CDA | Evidence Driven
CDA | Evidence Driven

Raltegravir

Details

Files
Generic Name:
Raltegravir
Project Status:
Complete
Therapeutic Area:
HIV
Manufacturer:
Merck Frosst Canada Ltd.
Brand Name:
Isentress
Project Line:
Reimbursement Review
Project Number:
SR0115-000
Performance Metric:
N/A — Predated performance metrics
Submission Type:
Initial
Indications:
HIV
Recommendation Type:
List with clinical criteria and/or conditions
Final Recommendation:

Files

Submission Status Report View PDF
Recommendation and Reasons View PDF
Summary of CEDAC Discussion View PDF
Overview of CDR Reports View PDF
Plain Language Recommendation View PDF
Last Updated : November 29, 2007